Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with advanced, refractory, or recurrent cervical or vaginal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
06/19/2013
Locations: Cancer Center, University of Virginia HSC, Charlottesville, Virginia
Conditions: Cervical Cancer, Vaginal Cancer
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin, leuprolide, flutamide, or bicalutamide may stop the adrenal glands from producing androgens. Combining chemotherapy with hormone therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus hormone therapy in treating patients who have... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/12/2013
Locations: Sentara Cancer Institute at Sentara Norfolk General Hospital, Norfolk, Virginia
Conditions: Prostate Cancer
Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known whether intravenous two-drug combination chemotherapy is more effective than intravenous and intraperitoneal infusions of three-drug combination chemotherapy for treating primary peritoneal or stage III epithelial ovarian cancer. PURPOSE: Randomized phase III trial to... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
05/24/2013
Locations: Cancer Center, University of Virginia HSC, Charlottesville, Virginia
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for ovarian or peritoneal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of paclitaxel plus cisplatin in treating patients who have residual disease after surgery to remove stage III or stage IV ovarian cancer or pri... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/24/2013
Locations: Cancer Center, University of Virginia HSC, Charlottesville, Virginia
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have stage III or stage IV ovarian epithelial or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
05/24/2013
Locations: Cancer Center at the University of Virginia, Charlottesville, Virginia
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells and decrease the need for surgery. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by observation or surgery to remove the bladder (cystectomy) in treating patients who have stage II or stage III cancer of the urothelium.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2013
Locations: Danville Regional Medical Center, Danville, Virginia
Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Terminated
RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: Cancer Center, University of Virginia HSC, Charlottesville, Virginia
Conditions: Ovarian Cancer
Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. It is not yet known whether chemotherapy alone is more effective than chemotherapy plus peripheral stem cell transplantation for ovarian epithelial cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of... Read More
Gender:
FEMALE
Ages:
65 years and below
Trial Updated:
04/10/2013
Locations: Veterans Affairs Medical Center - Richmond, Richmond, Virginia +1 locations
Conditions: Ovarian Cancer
Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Hormone therapy using tamoxifen and megestrol may fight endometrial cancer by blocking the absorption of estrogen. It is not yet known whether chemotherapy is more effective than hormone therapy in treating endometrial cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with that... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
04/10/2013
Locations: Cancer Center at the University of Virginia, Charlottesville, Virginia
Conditions: Endometrial Cancer
S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have metastatic or recurrent head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2013
Locations: Eastern Virginia Medical School, Norfolk, Virginia
Conditions: Head and Neck Cancer
Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
Completed
Sorafenib is being looked at in a number of solid tumor settings including breast cancer. This trial is designed as a pilot study to assess the safety and tolerability of a novel oral agent in combination with standard chemotherapy in the treatment of early stage node positive or otherwise high-risk breast cancer. If this should prove to be a tolerable regimen for patients, this would provide rationale for further studies in a larger randomized fashion.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/25/2013
Locations: Peninsula Cancer Institute, Newport News, Virginia
Conditions: Breast Cancer
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
Completed
In this randomized trial, we will investigate the activity and toxicity of two active regimens, gemcitabine/irinotecan and paclitaxel/carboplatin/Etoposide (both followed by ZD1839) in the first-line treatment of patients with carcinoma of unknown primary site.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2013
Locations: Cancer Outreach Associates, Abingdon, Virginia
Conditions: Neoplasms, Unknown Primary